- Home
- AMST vs MTVA Comparison
AMST vs MTVA Comparison
Compare AMST & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- MTVA
- Stock Information
- Founded
- AMST 2017
- MTVA 2014
- Country
- AMST United States
- MTVA United States
- Employees
- AMST N/A
- MTVA N/A
- Industry
- AMST Computer Software: Prepackaged Software
- MTVA
- Sector
- AMST Technology
- MTVA
- Exchange
- AMST Nasdaq
- MTVA NYSE
- Market Cap
- AMST 14.7M
- MTVA 14.3M
- IPO Year
- AMST 2020
- MTVA N/A
- Fundamental
- Price
- AMST $3.18
- MTVA $0.71
- Analyst Decision
- AMST
- MTVA Strong Buy
- Analyst Count
- AMST 0
- MTVA 2
- Target Price
- AMST N/A
- MTVA $7.50
- AVG Volume (30 Days)
- AMST 113.7K
- MTVA 64.8K
- Earning Date
- AMST 05-15-2025
- MTVA 08-13-2025
- Dividend Yield
- AMST N/A
- MTVA N/A
- EPS Growth
- AMST N/A
- MTVA N/A
- EPS
- AMST N/A
- MTVA N/A
- Revenue
- AMST $82,544.00
- MTVA N/A
- Revenue This Year
- AMST N/A
- MTVA N/A
- Revenue Next Year
- AMST N/A
- MTVA N/A
- P/E Ratio
- AMST N/A
- MTVA N/A
- Revenue Growth
- AMST N/A
- MTVA N/A
- 52 Week Low
- AMST $2.00
- MTVA $0.60
- 52 Week High
- AMST $6.27
- MTVA $4.36
- Technical
- Relative Strength Index (RSI)
- AMST 54.73
- MTVA N/A
- Support Level
- AMST $3.05
- MTVA N/A
- Resistance Level
- AMST $3.25
- MTVA N/A
- Average True Range (ATR)
- AMST 0.23
- MTVA 0.00
- MACD
- AMST -0.01
- MTVA 0.00
- Stochastic Oscillator
- AMST 31.40
- MTVA 0.00
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.